I think you have missed his point. It is highly unlikely that any further clinical trials will be required to obtain FDA approval for Ryoncil. Yes, further trials may be necessary for label extensions but there will be plenty of off label use in the meantime. So substantial revenues are virtually assured no matter what the outcome of the Phase 3 trials for CHF and CLBP. Ryoncil is our safety net.
I think you have missed his point. It is highly unlikely that...
-
- There are more pages in this discussion • 21,236 more messages in this thread...
This thread is closed.
You may not reply to this discussion at this time.
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.06 |
Change
0.030(2.91%) |
Mkt cap ! $1.210B | |||
| Open | High | Low | Value | Volume |
| $1.05 | $1.09 | $1.03 | $5.796M | 5.430M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 15990 | $1.06 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.08 | 48632 | 3 |
View Market Depth
| Last trade - 16.10pm 02/09/2024 (20 minute delay) ? |
| MSB (ASX) Chart |